ScholarWorks@경상국립대학교

초록

According to the Convention on Biological Diversity and the Nagoya Protocol, which is an annexed protocol, when using genetic resources, access permits shoul be obtained from the country providing genetic resources, and a benefit-sharing contract should be concluded with the genetic resource providers. If so, should the access and benefit-sharing procedures of the Nagoya Protocol be followed even when using genetic resource digital sequence information(DSI)? This is currently attracting attention as one of the most important issues in the Convention on Biological Diversity and the Nagoya Protocol. Today, many researchers and scientists mainly use the genetic resource DSI for research and development rather than the genetic resource itself. In addition, with the recent development of DNA sequencing technology, genetic resource DSI is rapidly accumulating in DBs, and is being used for various purposes such as research and commerce. Therefore, if the genetic resource DSI, which has been freely used so far, is subject to the Nagoya Protocol, it is likely to have a devastating effect on research and development in the field of biotechnology. For this reason, it is worth noting that the appropriateness, type, and scope of the gene source DSI terminology are being discussed in the biodiversity agreement, while the access and profit sharing of the Nagoya Protocol are sharply opposed between developed and developing countries. In response, the main office first wants to examine the background of the start of discussion of genetic source DSI in the biodiversity agreement and Nagoya Protocol, trends in discussions so far, and major agreements. Next, we would like to look at the main issues of genetic source DSI, such as the term, type and scope of genetic source DSI, and whether it is subject to Nagoya Protocol. Finally, based on these contents, I would like to present policy implications and countermeasures for the domestic bio industry.

키워드